No photo of Emmanuel Antonarakis

View Scopus Profile

Emmanuel Antonarakis

ASSOCIATE PROFESSOR

20022018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 16 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Castration Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Androgen Receptors Medicine & Life Sciences
Androgens Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2018

Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Antonarakis, E., Jan 1 2018, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journal › Article

Prostatic Neoplasms
Synthetic Lethal Mutations
abiraterone
olaparib

Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival

Antonarakis, E., Small, E. J., Petrylak, D. P., Quinn, D. I., Kibel, A. S., Chang, N. N., Dearstyne, E., Harmon, M., Campogan, D., Haynes, H., Vu, T., Sheikh, N. A. & Drake, C. G., Oct 1 2018, In : Clinical Cancer Research. 24, 19, p. 4662-4671 10 p.

Research output: Contribution to journal › Article

CD8 Antigens
Castration
Prostatic Neoplasms
Hormones
Phenotype

AR signaling in humanmalignancies: Prostate cancer and beyond

Antonarakis, E., Jan 18 2018, In : Cancers. 10, 1, 22.

Research output: Contribution to journal › Editorial

Androgen Receptors
Prostatic Neoplasms
Salivary Gland Neoplasms
Androgen Antagonists
Urinary Bladder Neoplasms

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Basch, E. M., Scholz, M., de Bono, J. S., Vogelzang, N., de Souza, P., Marx, G., Vaishampayan, U., George, S., Schwarz, J. K., Antonarakis, E., O'Sullivan, J. M., Kalebasty, A. R., Chi, K. N., Dreicer, R., Hutson, T. E., Dueck, A. C., Bennett, A. V., Dayan, E., Mangeshkar, M., Holland, J. & 2 othersWeitzman, A. L. & Scher, H. I., Jan 1 2018, (Accepted/In press) In : European Urology.

Research output: Contribution to journal › Article

Mitoxantrone
Castration
Pain Measurement
Prednisone
Prostatic Neoplasms

Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer: Is there enough evidence?

Antonarakis, E., Feb 20 2018, In : Journal of Clinical Oncology. 36, 6, p. 525-527 3 p.

Research output: Contribution to journal › Editorial

Circulating Neoplastic Cells
Castration
Prostatic Neoplasms